Drug resistance and tumor heterogeneity

CME Journal of Gynecologic Oncology

Volumn 7, Issue 1, 2002, Pages 25-28

  Geisler, John P ^a   Rose, Stephen L ^a   Geisler, Hans E ^a   Miller, Greg A ^a   Wiemann, Michael C ^a  

^a ST VINCENT HOSPITAL   (United States)

Author keywords

Breast cancer; Drug resistance; Other gynecologic malignancies; Ovarian cancer; Tumor heterogeneity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PLATINUM DERIVATIVE; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN MLH1; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR AP 1; TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; CANCER RESISTANCE; CANCER STAGING; CELL HETEROGENEITY; CHEMOSENSITIVITY; EPITHELIUM CELL; FEMALE; GENETIC STABILITY; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PROBLEM SOLVING; TUMOR CELL;

EID: 0036276101     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Mechanisms of tumor progression
2. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy
3. Procedures required to accomplish complete cytoredction of ovarian cancer: Is there a correlation with "biological aggressiveness" and survival
4. Optimal cytoreductive surgery in the elderly woman with stage IIIC serous cystadenocarcinoma of the ovary
5. Stratification of patients with epithelial ovarian carcinoma into high and low risk categories
6. Spontaneous development of drug resistance: Mismatch repair and p53 defects in resistance to cisplatin in human tumor cells
7. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer
8. BRCA1 dysfunction is common in ovarian cancer
9. Laser microdissection and microsatellite analyses of breast cancer reveal a high degree of tumor heterogeneity
10. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis
11. Intratumoral heterogeneity of DNA ploidy in breast carcinomas: A flow cytometric assessment of sampling techniques
12. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemprevention against multidrug resistance possible?
13. The apoptosis promoting bcl-2 homologues bak and nbk/bik overcome drug resistance in MDR-1-negative and MDR-1-overexpressing breast caner cell lines
14. Lack of bcl-2 persistence: As an independent prognostic indicator of poor prognosis in endometrial carcinoma
15. The role of HER-2 in drug-sensitivity in breast cancer
16. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay
17. Tumor heterogeneity and in vito chemosensitivity testing in ovarian cancer
18. Flow cytometry DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma
19. Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy
20. Heterogenous genetic alterations in ovarian mucinous tumors: Application and usefulness of laser capture microdissection
21. Cytogenetic observations of a human ovarian carcinoma clinically resistant to therapy
22. Two-dimensional gel analysis of protein expression in ovarian tumors shows a low degree intrammoral heterogeneity
23. Differences in hMSH2 expression and DNA index between the primary and metastases in patients with optimally cytoreduced stage IIIC and LV serous ovarian carcinoma
24. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer
25. A comparison of two commercially available in vitro chemosensitivity assays
26. Causes and consequences of microsatellite instability in endometrial carcinoma
27. Genotypic and phenotypic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair and KRAS2 occur
28. Genetic instability of microsatellites in endometrial carcinoma
29. Markov texture parameters as prognostic indicators in endometrial cancer
30. DNA index by image analysis in advanced endometrial carcinoma
31. Nuclear size, shape, and summed optical density in endometrial cancer
32. A difference in nuclear morphometry when frozen rather than fresh tissue is studied
33. Four-color multiparameter DNA flow cytometric method to study phenotypic intratumor heterogeneity in cervical cancer
34. Evidence of tumor heterogeneity in cervical cancers and lymph node metastases as determined by flow cytometry
35. Flow cytometric evaluation of early invasive cervical cancer
36. Drug resistance and experimental chemotherapy
37. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells
38. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter